Australian Dificid approval feathers Optimer's cap
This article was originally published in Scrip
Executive Summary
Amid reports that a number of major pharma companies including GlaxoSmithKline and AstraZeneca might be eyeing its possible acquisition, US firm Optimer Pharmaceuticals may have enhanced its eventual value by securing another regulatory approval for its only product Dificid (fidaxomicin).